G1 THERAPEUTICS INC. - COMMON STOCK

Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

07 ديسمبر 2022 18:04:19 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ديسمبر 2022 23:41:26 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

23 نوفمبر 2022 10:30:26 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Closing of Offering of Common Stock

22 نوفمبر 2022 16:01:04 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Pricing of Offering of Common Stock

17 نوفمبر 2022 20:12:26 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Proposed Public Offering of Common Stock

17 نوفمبر 2022 16:01:05 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

02 نوفمبر 2022 06:30:33 بحسب Nasdaq GlobeNewswire

Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

02 نوفمبر 2022 06:28:23 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2022 17:40:30 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

26 أكتوبر 2022 09:26:34 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022

19 أكتوبر 2022 12:30:57 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

10 أكتوبر 2022 06:30:06 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 أكتوبر 2022 17:00:53 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference

07 سبتمبر 2022 08:00:29 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Host Virtual R&D Day on September 15, 2022

06 سبتمبر 2022 07:00:15 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 سبتمبر 2022 17:22:08 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

03 أغسطس 2022 06:30:32 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أغسطس 2022 17:15:05 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

25 يوليو 2022 06:30:43 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022

20 يوليو 2022 09:00:31 بحسب Nasdaq GlobeNewswire